Combination radiotherapy and chemotherapy for P388 lymphocytic leukemia in vivo.
D000409:Alanine / Q000627:therapeutic use; D000818:Animals; D002945:Cisplatin / Q000627:therapeutic use; D003037:Cobalt Radioisotopes; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000532:radiotherapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D009368:Neoplasm Transplantation; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011379:Prognosis; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D014184:Transplantation, Homologous; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D003037:Cobalt Radioisotopes; D003561:Cytarabine; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D000409:Alanine; D002945:Cisplatin; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate